Study guide

17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED

Key Takeaways Explain This Topic AI

Ketorolac 10 mg IV relieves pain about as well as 15 or 30 mg, and ibuprofen 400 mg about as well as 600 or 800 mg; higher doses mainly add adverse effects.

Sub-dissociative ketamine (0.1 to 0.3 mg/kg IV) is an opioid-sparing analgesic, and infusing it over 10 to 15 minutes causes less dysphoria than an IV push.

ACEP's 2014 procedural sedation policy says sedation should not be delayed solely because of recent oral intake.

Ketamine sedation has two absolute contraindications in ACEP's ketamine guideline: age under 3 months and known or suspected schizophrenia.

Capnography detects hypoventilation during procedural sedation earlier than pulse oximetry, especially when supplemental oxygen is given.

Last updated: October 2026

17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED

Note

Exam scope: 2025 outline subtopic 2B9 (Pharmacotherapy for Pain and Sedation). Intubation drugs and post-intubation analgosedation are covered in Chapter 4, sickle cell pain in Section 10.3, and discharge opioid stewardship in Section 14.2.

Principles of ED Analgesia

Pain is one of the most common reasons for an ED visit, and undertreatment is well documented, with documented disparities by race and ethnicity. Good practice is:

Assess and reassess with a validated scale and treat promptly; giving analgesia does not mask surgical diagnoses.

Use multimodal therapy : combine drugs with different mechanisms (acetaminophen, NSAIDs, local or regional anesthesia, ketamine), with opioids added when needed.

Choose the route that is fastest but least invasive. Intranasal fentanyl or ketamine works quickly in children without an IV.

Non-Opioid Analgesics

  • Agent Typical ED dose Key points
  • Acetaminophen 1 g orally or IV (adult) Oral works as well as IV when the patient can swallow; IV costs more
  • Ibuprofen 400 mg orally 400, 600 and 800 mg gave similar pain relief in an ED trial
  • Ketorolac 10 mg IV 10, 15 and 30 mg IV gave similar relief: a ceiling effect
  • Topical NSAIDs Diclofenac gel Useful for sprains and strains with less systemic exposure

Sub-dissociative ketamine 0.1 to 0.3 mg/kg IV over 10 to 15 minutes Comparable to morphine 0.1 mg/kg in trials; infusion causes less dysphoria and fewer feelings of unreality than a push

IV lidocaine About 1.5 mg/kg over 10 minutes Studied for renal colic, with mixed results; avoid in heart block and with other sodium-channel blockers

Suzetrigine (FDA-approved 2025) 100 mg orally, then 50 mg every 12 hours First selective NaV1.8 blocker for moderate to severe acute pain; avoid with strong CYP3A inhibitors; modest efficacy

NSAIDs are avoided in AKI or advanced CKD, active GI bleeding, late pregnancy and when bleeding risk is high. Older adults usually tolerate short courses with appropriate precautions.

Opioids

  • Opioid Typical IV starting dose Notes
  • Morphine 0.1 mg/kg Active metabolite (M6G) accumulates in kidney failure; histamine release

Hydromorphone 0.015 mg/kg (often 0.5 mg in older or opioid-naive patients) About 5 to 7 times as potent as morphine; dose errors are common

Fentanyl 1 mcg/kg IV; 1.5 mcg/kg intranasal (maximum 100 mcg) Fast onset, little histamine release; preferred with hypotension or kidney impairment

In kidney impairment , avoid morphine, codeine, meperidine and tramadol accumulation; fentanyl and cautious hydromorphone are preferred.

Older adults: start low (often half the usual dose) and watch for delirium and respiratory depression.

Discharge prescriptions: the 2022 CDC guideline says nonopioid therapy is at least as effective as opioids for many acute pain conditions. When an opioid is needed, prescribe an immediate-release product, the lowest effective dose, and no more than the expected duration of severe pain. Check the prescription drug monitoring program and co-prescribe naloxone for patients at risk (Section 14.2).

Regional Anesthesia

Ultrasound-guided nerve blocks give strong analgesia with little systemic effect:

Fascia iliaca or femoral nerve block for hip fracture reduces opioid use and is associated with less delirium in older adults.

Hematoma blocks for distal radius fractures, digital blocks, and serratus anterior blocks for rib fractures.

The pharmacist checks the total local anesthetic dose across all sites against maximum doses and keeps lipid emulsion available (Section 9.4).

  • Procedural Sedation and Analgesia (PSA)
  • The Sedation Continuum (ASA)
  • Level Response Airway and breathing Circulation
  • Minimal (anxiolysis) Normal response to voice Unaffected Unaffected
  • Moderate Purposeful response to voice or light touch No intervention needed Usually maintained
  • Deep Purposeful response only to repeated or painful stimulation Intervention may be needed Usually maintained
  • General anesthesia Not rousable Intervention often needed May be impaired

Dissociative (ketamine) Trance-like state with analgesia and amnesia Airway reflexes and breathing usually preserved Usually maintained or increased

Sedation is a continuum, so the team must be able to rescue a patient from one level deeper than intended.

Presedation Assessment

ASA physical status class, airway exam (signs of difficult bag-mask ventilation or intubation), allergies, prior sedation problems, and current medications.

Fasting: ACEP's 2014 clinical policy states that procedural sedation should not be delayed solely because of recent oral intake . Aspiration during ED sedation is very rare.

Informed consent and a plan for the depth needed.

Sedative Agents

Agent Typical IV dose Strengths Pitfalls

Ketamine 1 to 2 mg/kg IV (dissociation above about 1 to 1.5 mg/kg); 4 to 5 mg/kg IM Analgesia, preserved breathing and airway reflexes, stable blood pressure Vomiting (ondansetron helps), emergence agitation in adults (pretreatment with low-dose midazolam helps), laryngospasm (rare), rise in BP and heart rate

Propofol 1 mg/kg, then 0.5 mg/kg every 3 to 5 minutes Rapid onset and recovery, antiemetic Apnea, hypotension; no analgesia

Ketofol (ketamine plus propofol) For example 0.5 mg/kg of each Ketamine offsets propofol's hypotension, and propofol offsets ketamine's vomiting Two drugs means a higher risk of mixing errors

Etomidate 0.1 to 0.15 mg/kg Stable hemodynamics Myoclonus, brief sedation, no analgesia

Midazolam plus fentanyl Midazolam about 0.02 to 0.05 mg/kg plus fentanyl 0.5 to 1 mcg/kg, titrated Reversible (flumazenil, naloxone) Respiratory depression is additive; slower to titrate

Dexmedetomidine Loading 0.5 to 1 mcg/kg over 10 minutes, then infusion Calm, cooperative sedation for imaging Bradycardia, hypotension, slow onset; poor for painful procedures

ACEP ketamine guideline (2011) absolute contraindications: age under 3 months (higher airway risk) and known or suspected schizophrenia , even when stable. Relative concerns include procedures that stimulate the back of the throat, active respiratory infection, significant coronary disease or uncontrolled hypertension, and porphyria or thyroid disease. Routine atropine or glycopyrrolate premedication is no longer recommended.

Laryngospasm with ketamine is rare (well under 1%). Treat it with jaw thrust, bag-mask ventilation with positive pressure and, rarely, a small dose of succinylcholine.

Monitoring and Rescue

A dedicated clinician watches the patient continuously, separate from the person doing the procedure.

Continuous pulse oximetry, cardiac monitoring and blood pressure every 3 to 5 minutes.

Capnography shows hypoventilation (rising end-tidal CO2, flattening waveform, apnea) before pulse oximetry falls , especially when the patient is receiving supplemental oxygen. ACEP supports its use.

Have suction, bag-mask, airway equipment, naloxone and flumazenil at the bedside.

Recovery and discharge: return to baseline mental status and vital signs, adequate pain control, and a responsible adult escort, with written instructions to avoid driving and hazardous activities for the rest of the day.